Benadryl
Relapsing Chronic Myelogenous Leukemia
City of Hope Medical CenterPhase 2Dormant
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Relapsing Chronic Myelogenous Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Therapeutic Allogeneic Lymphocytes University of Chicago | Phase 2 | BBB |
Cediranib M.D. Anderson Cancer Center | Phase 2 | BB |
(+)-VINCRISTINE M.D. Anderson Cancer Center | Phase 2 | BB |
Irinotecan OHSU Knight Cancer Institute | Phase 2 | BB |
Vorinostat OHSU Knight Cancer Institute | Phase 2 | B |
View all 17 →
Same molecule, other indications
Benadryl is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →